SAT-3247

· Satellos Bioscience, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SAT-3247, covering 2026-04-15 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 [Phase 2]

See pricing